News
12-10-2025, 10:10 AM
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
More... (https://www.news-medical.net/news/20251210/Addition-of-tucatinib-to-the-standard-of-care-delays-disease-progression-in-HER2-positive-metastatic-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20251210/Addition-of-tucatinib-to-the-standard-of-care-delays-disease-progression-in-HER2-positive-metastatic-breast-cancer.aspx)